Institute for Applied Cancer Science
MD Anderson is known for providing cancer patients with exceptional care, which includes early access to innovative new treatments through clinical trials. IACS is a new integrated model for drug development that uniquely combines the drug discovery capabilities of the biopharmaceutical industry with deep biological insights from academia and the expertise of MD Anderson's top clinicians. Our singular focus is our patients as we aim to rapidly develop novel, effective, and safe therapeutics that improve patient health.
IACS executes programs with the highest probability of clinical success in a rigorous, goal-oriented, and data-driven manner. By teaming with our physician-scientists throughout product development, we employ a Bench-at-Bedside approach to position our novel therapeutics in specific patient populations with unmet medical needs.